Stakeholder Advice To Add-On Aspirants: Meet With CMS Prior To Approval
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking new-technology "add-on" payments under CMS' inpatient prospective payment system should meet with the agency well before a product gains premarket approval, according to Hospital & Ambulatory Group Director Liz Richter
You may also be interested in...
CMS New Tech Add-On Interpretation Contested By Industry Reps
Medtronic will attempt to persuade CMS that the firm's Kinetra deep-brain stimulation device marks a substantial clinical improvement over its predecessor - the dual-implant Soletra - and therefore qualifies for a new technology "add-on" payment
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.